H. R. 6—117 
‘‘(3) provides data on substance use disorder prevention 
and treatment strategies in different regions of and populations 
in the United States; 
‘‘(4) identifies information on alternatives to controlled sub-
stances for pain management, such as approaches studied by 
the National Institutes of Health Pain Consortium, the National 
Center for Complimentary and Integrative Health, and other 
institutes and centers at the National Institutes of Health, 
as appropriate; and 
‘‘(5) identifies guidelines and best practices for health care 
providers regarding treatment of substance use disorders. 
‘‘(b) CONTROLLED SUBSTANCE DEFINED.—In this section, the 
term ‘controlled substance’ has the meaning given that term in 
section 102 of the Controlled Substances Act (21 U.S.C. 802).’’. 
SEC. 
7022. 
INTERDEPARTMENTAL 
SUBSTANCE 
USE 
DISORDERS 
COORDINATING COMMITTEE. 
(a) ESTABLISHMENT.—Not later than 3 months after the date 
of the enactment of this Act, the Secretary of Health and Human 
Services (in this section referred to as the ‘‘Secretary’’) shall, in 
coordination with the Director of National Drug Control Policy, 
establish a committee, to be known as the Interdepartmental Sub-
stance Use Disorders Coordinating Committee (in this section 
referred to as the ‘‘Committee’’), to coordinate Federal activities 
related to substance use disorders. 
(b) MEMBERSHIP.— 
(1) FEDERAL MEMBERS.—The Committee shall be composed 
of the following Federal representatives, or the designees of 
such representatives: 
(A) The Secretary, who shall serve as the Chair of 
the Committee. 
(B) The Attorney General of the United States. 
(C) The Secretary of Labor. 
(D) The Secretary of Housing and Urban Development. 
(E) The Secretary of Education. 
(F) The Secretary of Veterans Affairs. 
(G) The Commissioner of Social Security. 
(H) The Assistant Secretary for Mental Health and 
Substance Use. 
(I) The Director of National Drug Control Policy. 
(J) Representatives of other Federal agencies that sup-
port or conduct activities or programs related to substance 
use disorders, as determined appropriate by the Secretary. 
(2) NON-FEDERAL MEMBERS.—The Committee shall include 
a minimum of 15 non-Federal members appointed by the Sec-
retary, of which— 
(A) at least two such members shall be an individual 
who has received treatment for a diagnosis of a substance 
use disorder; 
(B) at least two such members shall be a director 
of a State substance abuse agency; 
(C) at least two such members shall be a representative 
of a leading research, advocacy, or service organization 
for adults with substance use disorder; 
(D) at least two such members shall—
H. R. 6—118 
(i) be a physician, licensed mental health profes-
sional, advance practice registered nurse, or physician 
assistant; and 
(ii) have experience in treating individuals with 
substance use disorders; 
(E) at least one such member shall be a substance 
use disorder treatment professional who provides treatment 
services at a certified opioid treatment program; 
(F) at least one such member shall be a substance 
use disorder treatment professional who has research or 
clinical experience in working with racial and ethnic 
minority populations; 
(G) at least one such member shall be a substance 
use disorder treatment professional who has research or 
clinical mental health experience in working with medically 
underserved populations; 
(H) at least one such member shall be a State-certified 
substance use disorder peer support specialist; 
(I) at least one such member shall be a drug court 
judge or a judge with experience in adjudicating cases 
related to substance use disorder; 
(J) at least one such member shall be a public safety 
officer with extensive experience in interacting with adults 
with a substance use disorder; and 
(K) at least one such member shall be an individual 
with experience providing services for homeless individuals 
with a substance use disorder. 
(c) TERMS.— 
(1) IN GENERAL.—A member of the Committee appointed 
under subsection (b)(2) shall be appointed for a term of 3 
years and may be reappointed for one or more 3-year terms. 
(2) VACANCIES.—A vacancy on the Committee shall be filled 
in the same manner in which the original appointment was 
made. Any individual appointed to fill a vacancy for an 
unexpired term shall be appointed for the remainder of such 
term and may serve after the expiration of such term until 
a successor has been appointed. 
(d) MEETINGS.—The Committee shall meet not fewer than two 
times each year. 
(e) DUTIES.—The Committee shall— 
(1) identify areas for improved coordination of activities, 
if any, related to substance use disorders, including research, 
services, supports, and prevention activities across all relevant 
Federal agencies; 
(2) identify and provide to the Secretary recommendations 
for improving Federal programs for the prevention and treat-
ment of, and recovery from, substance use disorders, including 
by expanding access to prevention, treatment, and recovery 
services; 
(3) analyze substance use disorder prevention and treat-
ment strategies in different regions of and populations in the 
United States and evaluate the extent to which Federal sub-
stance use disorder prevention and treatment strategies are 
aligned with State and local substance use disorder prevention 
and treatment strategies;
H. R. 6—119 
(4) make recommendations to the Secretary regarding any 
appropriate changes with respect to the activities and strategies 
described in paragraphs (1) through (3); 
(5) make recommendations to the Secretary regarding 
public participation in decisions relating to substance use dis-
orders and the process by which public feedback can be better 
integrated into such decisions; and 
(6) make recommendations to ensure that substance use 
disorder research, services, supports, and prevention activities 
of the Department of Health and Human Services and other 
Federal agencies are not unnecessarily duplicative. 
(f) ANNUAL REPORT.—Not later than 1 year after the date 
of the enactment of this Act, and annually thereafter for the life 
of the Committee, the Committee shall publish on the Internet 
website of the Department of Health and Human Services, which 
may include the public information dashboard established under 
section 1711 of the Public Health Service Act, as added by section 
7021, a report summarizing the activities carried out by the Com-
mittee pursuant to subsection (e), including any findings resulting 
from such activities. 
(g) WORKING GROUPS.—The Committee may establish working 
groups for purposes of carrying out the duties described in sub-
section (e). Any such working group shall be composed of members 
of the Committee (or the designees of such members) and may 
hold such meetings as are necessary to enable the working group 
to carry out the duties delegated to the working group. 
(h) FEDERAL ADVISORY COMMITTEE ACT.—The Federal Advisory 
Committee Act (5 U.S.C. App.) shall apply to the Committee only 
to the extent that the provisions of such Act do not conflict with 
the requirements of this section. 
(i) SUNSET.—The Committee shall terminate on the date that 
is 6 years after the date on which the Committee is established 
under subsection (a). 
SEC. 7023. NATIONAL MILESTONES TO MEASURE SUCCESS IN CUR-
TAILING THE OPIOID CRISIS. 
(a) IN GENERAL.—Not later than 180 days after the date of 
enactment of this Act, the Secretary of Health and Human Services 
(referred to in this section as the ‘‘Secretary’’), in coordination 
with the Administrator of the Drug Enforcement Administration 
and the Director of the Office of National Drug Control Policy, 
shall develop or identify existing national indicators (referred to 
in this section as the ‘‘national milestones’’) to measure success 
in curtailing the opioid crisis, with the goal of significantly reversing 
the incidence and prevalence of opioid misuse and abuse, and opioid- 
related morbidity and mortality in the United States within 5 
years of such date of enactment. 
(b) NATIONAL MILESTONES TO END THE OPIOID CRISIS.—The 
national milestones under subsection (a) shall include the following: 
(1) Not fewer than 10 indicators or metrics to accurately 
and expediently measure progress in meeting the goal described 
in subsection (a), which shall, as appropriate, include, indicators 
or metrics related to— 
(A) the number of fatal and non-fatal opioid overdoses; 
(B) the number of emergency room visits related to 
opioid misuse and abuse;
H. R. 6—120 
(C) the number of individuals in sustained recovery 
from opioid use disorder; 
(D) the number of infections associated with illicit drug 
use, such as HIV, viral hepatitis, and infective endocarditis, 
and available capacity for treating such infections; 
(E) the number of providers prescribing medication- 
assisted treatment for opioid use disorders, including in 
primary care settings, community health centers, jails, and 
prisons; 
(F) the number of individuals receiving treatment for 
opioid use disorder; and 
(G) additional indicators or metrics, as appropriate, 
such as metrics pertaining to specific populations, including 
women and children, American Indians and Alaskan 
Natives, individuals living in rural and non-urban areas, 
and justice-involved populations, that would further clarify 
the progress made in addressing the opioid crisis. 
(2) A reasonable goal, such as a percentage decrease or 
other specified metric, that signifies progress in meeting the 
goal described in subsection (a), and annual targets to help 
achieve that goal. 
(c) CONSIDERATION OF OTHER SUBSTANCE USE DISORDERS.— 
In developing the national milestones under subsection (b), the 
Secretary shall, as appropriate, consider other substance use dis-
orders in addition to opioid use disorder. 
(d) EXTENSION OF PERIOD.—If the Secretary determines that 
the goal described in subsection (a) will not be achieved with respect 
to any indicator or metric established under subsection (b)(2) within 
5 years of the date of enactment of this Act, the Secretary may 
extend the timeline for meeting such goal with respect to that 
indicator or metric. The Secretary shall include with any such 
extension a rationale for why additional time is needed and informa-
tion on whether significant changes are needed in order to achieve 
such goal with respect to the indicator or metric. 
(e) ANNUAL STATUS UPDATE.—Not later than one year after 
the date of enactment of this Act, the Secretary shall make available 
on the Internet website of the Department of Health and Human 
Services, and submit to the Committee on Health, Education, Labor, 
and Pensions of the Senate and the Committee on Energy and 
Commerce of the House of Representatives, an update on the 
progress, including expected progress in the subsequent year, in 
achieving the goals detailed in the national milestones. Each such 
update shall include the progress made in the first year or since 
the previous report, as applicable, in meeting each indicator or 
metric in the national milestones. 
SEC. 7024. STUDY ON PRESCRIBING LIMITS. 
Not later than 2 years after the date of enactment of this 
Act, the Secretary of Health and Human Services, in consultation 
with the Attorney General of the United States, shall submit to 
the Committee on Health, Education, Labor, and Pensions of the 
Senate and the Committee on Energy and Commerce of the House 
of Representatives a report on the impact of Federal and State 
laws and regulations that limit the length, quantity, or dosage 
of opioid prescriptions. Such report shall address— 
(1) the impact of such limits on—
H. R. 6—121 
(A) the incidence and prevalence of overdose related 
to prescription opioids; 
(B) the incidence and prevalence of overdose related 
to illicit opioids; 
(C) the prevalence of opioid use disorders; 
(D) medically appropriate use of, and access to, opioids, 
including any impact on travel expenses and pain manage-
ment outcomes for patients, whether such limits are associ-
ated with significantly higher rates of negative health out-
comes, including suicide, and whether the impact of such 
limits differs based on the clinical indication for which 
opioids are prescribed; 
(2) whether such limits lead to a significant increase in 
burden for prescribers of opioids or prescribers of treatments 
for opioid use disorder, including any impact on patient access 
to treatment, and whether any such burden is mitigated by 
any factors such as electronic prescribing or telemedicine; and 
(3) the impact of such limits on diversion or misuse of 
any controlled substance in schedule II, III, or IV of section 
202(c) of the Controlled Substances Act (21 U.S.C. 812(c)). 
Subtitle D—Ensuring Access to Quality 
Sober Living 
SEC. 7031. NATIONAL RECOVERY HOUSING BEST PRACTICES. 
Part D of title V of the Public Health Service Act (42 U.S.C. 
290dd et seq.) is amended by adding at the end the following 
new section: 
‘‘SEC. 550. NATIONAL RECOVERY HOUSING BEST PRACTICES. 
‘‘(a) BEST PRACTICES FOR OPERATING RECOVERY HOUSING.— 
‘‘(1) IN GENERAL.—The Secretary, in consultation with the 
individuals and entities specified in paragraph (2), shall identify 
or facilitate the development of best practices, which may 
include model laws for implementing suggested minimum 
standards, for operating recovery housing. 
‘‘(2) 
CONSULTATION.—In 
carrying 
out 
the 
activities 
described in paragraph (1), the Secretary shall consult with, 
as appropriate— 
‘‘(A) relevant divisions of the Department of Health 
and Human Services, including the Substance Abuse and 
Mental Health Services Administration, the Office of 
Inspector General, the Indian Health Service, and the Cen-
ters for Medicare & Medicaid Services; 
‘‘(B) the Secretary of Housing and Urban Development; 
‘‘(C) directors or commissioners, as applicable, of State 
health departments, tribal health departments, State Med-
icaid programs, and State insurance agencies; 
‘‘(D) representatives of health insurance issuers; 
‘‘(E) national accrediting entities and reputable pro-
viders of, and analysts of, recovery housing services, 
including Indian tribes, tribal organizations, and tribally 
designated housing entities that provide recovery housing 
services, as applicable; 
‘‘(F) individuals with a history of substance use dis-
order; and
H. R. 6—122 
‘‘(G) other stakeholders identified by the Secretary. 
‘‘(b) IDENTIFICATION
OF
FRAUDULENT
RECOVERY
HOUSING 
OPERATORS.— 
‘‘(1) IN GENERAL.—The Secretary, in consultation with the 
individuals and entities described in paragraph (2), shall iden-
tify or facilitate the development of common indicators that 
could be used to identify potentially fraudulent recovery housing 
operators. 
‘‘(2) 
CONSULTATION.—In 
carrying 
out 
the 
activities 
described in paragraph (1), the Secretary shall consult with, 
as appropriate, the individuals and entities specified in sub-
section (a)(2) and the Attorney General of the United States. 
‘‘(3) REQUIREMENTS.— 
‘‘(A) PRACTICES FOR IDENTIFICATION AND REPORTING.— 
In carrying out the activities described in paragraph (1), 
the Secretary shall consider how law enforcement, public 
and private payers, and the public can best identify and 
report fraudulent recovery housing operators. 
‘‘(B) FACTORS TO BE CONSIDERED.—In carrying out the 
activities described in paragraph (1), the Secretary shall 
identify or develop indicators, which may include indicators 
related to— 
‘‘(i) unusual billing practices; 
‘‘(ii) average lengths of stays; 
‘‘(iii) excessive levels of drug testing (in terms of 
cost or frequency); and 
‘‘(iv) unusually high levels of recidivism. 
‘‘(c) DISSEMINATION.—The Secretary shall, as appropriate, 
disseminate the best practices identified or developed under sub-
section (a) and the common indicators identified or developed under 
subsection (b) to— 
‘‘(1) State agencies, which may include the provision of 
technical assistance to State agencies seeking to adopt or imple-
ment such best practices; 
‘‘(2) Indian tribes, tribal organizations, and tribally des-
ignated housing entities; 
‘‘(3) the Attorney General of the United States; 
‘‘(4) the Secretary of Labor; 
‘‘(5) the Secretary of Housing and Urban Development; 
‘‘(6) State and local law enforcement agencies; 
‘‘(7) health insurance issuers; 
‘‘(8) recovery housing entities; and 
‘‘(9) the public. 
‘‘(d) REQUIREMENTS.—In carrying out the activities described 
in subsections (a) and (b), the Secretary, in consultation with appro-
priate individuals and entities described in subsections (a)(2) and 
(b)(2), shall consider how recovery housing is able to support 
recovery and prevent relapse, recidivism, or overdose (including 
overdose death), including by improving access and adherence to 
treatment, including medication-assisted treatment. 
‘‘(e) RULE OF CONSTRUCTION.—Nothing in this section shall 
be construed to provide the Secretary with the authority to require 
States to adhere to minimum standards in the State oversight 
of recovery housing. 
‘‘(f) DEFINITIONS.—In this section: 
‘‘(1) The term ‘recovery housing’ means a shared living 
environment free from alcohol and illicit drug use and centered
H. R. 6—123 
on peer support and connection to services that promote sus-
tained recovery from substance use disorders. 
‘‘(2) The terms ‘Indian tribe’ and ‘tribal organization’ have 
the meanings given those terms in section 4 of the Indian 
Self-Determination and Education Assistance Act (25 U.S.C. 
5304). 
‘‘(3) The term ‘tribally designated housing entity’ has the 
meaning given that term in section 4 of the Native American 
Housing Assistance and Self-Determination Act of 1996 (25 
U.S.C. 4103). 
‘‘(g) AUTHORIZATION
OF APPROPRIATIONS.—To carry out this 
section, there is authorized to be appropriated $3,000,000 for the 
period of fiscal years 2019 through 2021.’’. 
Subtitle E—Advancing Cutting Edge 
Research 
SEC. 7041. UNIQUE RESEARCH INITIATIVES. 
Section 402(n)(1) of the Public Health Service Act (42 U.S.C. 
282(n)(1)) is amended— 
(1) in subparagraph (A), by striking ‘‘or’’; 
(2) in subparagraph (B), by striking the period and 
inserting ‘‘; or’’; and 
(3) by adding at the end the following: 
‘‘(C) high impact cutting-edge research that fosters sci-
entific creativity and increases fundamental biological 
understanding leading to the prevention, diagnosis, or 
treatment of diseases and disorders, or research urgently 
required to respond to a public health threat.’’. 
SEC. 7042. PAIN RESEARCH. 
Section 409J(b) of the Public Health Service Act (42 U.S.C. 
284q(b)) is amended— 
(1) in paragraph (5)— 
(A) in subparagraph (A), by striking ‘‘and treatment 
of pain and diseases and disorders associated with pain’’ 
and inserting ‘‘treatment, and management of pain and 
diseases and disorders associated with pain, including 
information on best practices for the utilization of non- 
pharmacologic treatments, non-addictive medical products, 
and other drugs or devices approved or cleared by the 
Food and Drug Administration’’; 
(B) in subparagraph (B), by striking ‘‘on the symptoms 
and causes of pain;’’ and inserting the following: ‘‘on— 
‘‘(i) the symptoms and causes of pain, including 
the identification of relevant biomarkers and screening 
models and the epidemiology of acute and chronic pain; 
‘‘(ii) the diagnosis, prevention, treatment, and 
management of acute and chronic pain, including with 
respect to non-pharmacologic treatments, non-addictive 
medical products, and other drugs or devices approved 
or cleared by the Food and Drug Administration; and 
‘‘(iii) risk factors for, and early warning signs of, 
substance use disorders in populations with acute and 
chronic pain; and’’; and
H. R. 6—124 
(C) by striking subparagraphs (C) through (E) and 
inserting the following: 
‘‘(C) make recommendations to the Director of NIH— 
‘‘(i) to ensure that the activities of the National 
Institutes of Health and other Federal agencies are 
free of unnecessary duplication of effort; 
‘‘(ii) on how best to disseminate information on 
pain care and epidemiological data related to acute 
and chronic pain; and 
‘‘(iii) on how to expand partnerships between public 
entities and private entities to expand collaborative, 
cross-cutting research.’’; 
(2) by redesignating paragraph (6) as paragraph (7); and 
(3) by inserting after paragraph (5) the following: 
‘‘(6) REPORT.—The Secretary shall ensure that rec-
ommendations and actions taken by the Director with respect 
to the topics discussed at the meetings described in paragraph 
(4) are included in appropriate reports to Congress.’’. 
Subtitle F—Jessie’s Law 
SEC. 7051. INCLUSION OF OPIOID ADDICTION HISTORY IN PATIENT 
RECORDS. 
(a) BEST PRACTICES.— 
(1) IN
GENERAL.—Not later than 1 year after the date 
of enactment of this Act, the Secretary of Health and Human 
Services (in this section referred to as the ‘‘Secretary’’), in 
consultation with appropriate stakeholders, including a patient 
with a history of opioid use disorder, an expert in electronic 
health records, an expert in the confidentiality of patient health 
information and records, and a health care provider, shall iden-
tify or facilitate the development of best practices regarding— 
(A) the circumstances under which information that 
a patient has provided to a health care provider regarding 
such patient’s history of opioid use disorder should, only 
at the patient’s request, be prominently displayed in the 
medical records (including electronic health records) of such 
patient; 
(B) what constitutes the patient’s request for the pur-
pose described in subparagraph (A); and 
(C) the process and methods by which the information 
should be so displayed. 
(2) DISSEMINATION.—The Secretary shall disseminate the 
best practices developed under paragraph (1) to health care 
providers and State agencies. 
(b) REQUIREMENTS.—In identifying or facilitating the develop-
ment of best practices under subsection (a), as applicable, the Sec-
retary, in consultation with appropriate stakeholders, shall consider 
the following: 
(1) The potential for addiction relapse or overdose, 
including overdose death, when opioid medications are pre-
scribed to a patient recovering from opioid use disorder. 
(2) The benefits of displaying information about a patient’s 
opioid use disorder history in a manner similar to other poten-
tially lethal medical concerns, including drug allergies and 
contraindications.
H. R. 6—125 
(3) The importance of prominently displaying information 
about a patient’s opioid use disorder when a physician or med-
ical professional is prescribing medication, including methods 
for avoiding alert fatigue in providers. 
(4) The importance of a variety of appropriate medical 
professionals, including physicians, nurses, and pharmacists, 
having access to information described in this section when 
prescribing or dispensing opioid medication, consistent with 
Federal and State laws and regulations. 
(5) The importance of protecting patient privacy, including 
the requirements related to consent for disclosure of substance 
use disorder information under all applicable laws and regula-
tions. 
(6) All applicable Federal and State laws and regulations. 
SEC. 7052. COMMUNICATION WITH FAMILIES DURING EMERGENCIES. 
(a) PROMOTING
AWARENESS
OF
AUTHORIZED
DISCLOSURES 
DURING EMERGENCIES.—The Secretary of Health and Human Serv-
ices shall annually notify health care providers regarding permitted 
disclosures under Federal health care privacy law during emer-
gencies, including overdoses, of certain health information to fami-
lies, caregivers, and health care providers. 
(b) USE OF MATERIAL.—For the purposes of carrying out sub-
section (a), the Secretary of Health and Human Services may use 
material produced under section 7053 of this Act or section 11004 
of the 21st Century Cures Act (42 U.S.C. 1320d–2 note). 
SEC. 7053. DEVELOPMENT AND DISSEMINATION OF MODEL TRAINING 
PROGRAMS FOR SUBSTANCE USE DISORDER PATIENT 
RECORDS. 
(a) INITIAL PROGRAMS AND MATERIALS.—Not later than 1 year 
after the date of the enactment of this Act, the Secretary of Health 
and Human Services (in this section referred to as the ‘‘Secretary’’), 
in consultation with appropriate experts, shall identify the following 
model programs and materials (or if no such programs or materials 
exist, recognize private or public entities to develop and disseminate 
such programs and materials): 
(1) Model programs and materials for training health care 
providers (including physicians, emergency medical personnel, 
psychiatrists, psychologists, counselors, therapists, nurse practi-
tioners, physician assistants, behavioral health facilities and 
clinics, care managers, and hospitals, including individuals such 
as general counsels or regulatory compliance staff who are 
responsible for establishing provider privacy policies) con-
cerning the permitted uses and disclosures, consistent with 
the standards and regulations governing the privacy and secu-
rity of substance use disorder patient records promulgated by 
the Secretary under section 543 of the Public Health Service 
Act (42 U.S.C. 290dd–2) for the confidentiality of patient 
records. 
(2) Model programs and materials for training patients 
and their families regarding their rights to protect and obtain 
information under the standards and regulations described in 
paragraph (1). 
(b) REQUIREMENTS.—The model programs and materials 
described in paragraphs (1) and (2) of subsection (a) shall address 
circumstances under which disclosure of substance use disorder 
patient records is needed to—